QNRX (Quoin Pharmaceuticals) Rega marang bathi mangsa ngarep

QNRX (quoinpharma.com) - tandha merek perusahaan

Quoin Pharmaceuticals (QNRX) maintains an impeccable reputation in the therapy of rare dermatoses. The company's forward P/E ratio visualizes this status, where the 0.00 mark indicates the level of investment risk. The brand attracts leading biochemists with generous RSU packages. High profitability is driven by the global sale of patented formulas with minimal production costs.

Pangali Forward P/E: Quoin Pharmaceuticals (QNRX) kanggo 04.07.2022 - 17.11.2026

quoinpharma.com (QNRX) - rincian metrik lan laporan keuangan

Analisis wiwitan perusahaan:Quoin Pharmaceuticals Ltd QNRX
Produk mawa merek Quoin Pharmaceuticals

Quoin Pharmaceuticals (QNRX) focuses on therapies for ultra-rare dermatological diseases, which, combined with regular equity dilution, complicates profit forecasting. The forward P/E ratio relates the current share price to the expected net income for the following year; therefore, fluctuations in the company's projected P/E reflect the market's reassessment of risks associated with prolonged clinical trials and the volatility of the business's fundamental value.